http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2007525449-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-739 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-165 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-661 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-6615 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-739 |
| filingDate | 2004-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2007-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2007525449-A |
| titleOfInvention | Lysophosphatidic acid analogs and methods for inhibiting neointima formation |
| abstract | Phospholipid growth factor lysophosphatidic acid (LPA) containing unsaturated fatty acids (18: 1, 18: 2 and 20: 4) and fatty alcohols containing hydrocarbon chains with more than 4 carbons, this is atherosclerosis It is possible to induce the rapid formation of neointimal, the first step in the development of sexual spots. LPA with saturated fatty acids does not induce neointima formation. Rosiglitazone, a peroxisome proliferator-activated receptor gamma (PPARγ) specific agonist, also induced prominent formation of the neointima. GW9662, a selective and irreversible antagonist of PPARγ, abrogates neointimal formation induced by LPA and rosiglitazone, indicating that LPA-induced neointimal formation requires activation of PPARγ It suggests. These data indicate that LPA analogs that bind to PPARγ but do not activate downstream signaling, or antagonists of PPARγ that inhibit PPARγ signaling, prevent and / or treat neointimal formation and atherosclerosis It is useful for |
| priorityDate | 2003-04-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 382.